For the quarter ending 2026-03-31, TECX had -$17,491K decrease in cash & cash equivalents over the period. -$18,432K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -25,241 | -19,226 | -19,035 | -35,890 |
| Depreciation and amortization expense | 304 | 333 | 342 | 700 |
| Stock-based compensation expense | 3,205 | 2,989 | 2,817 | 4,691 |
| Loss on sale of property and equipment | -23 | 0 | -93 | -60 |
| Reduction in the carrying amount of the operating right-of-use assets | 496 | 548 | 535 | 1,035 |
| Change in fair value of safe liabilities | - | 0 | 0 | 0 |
| Prepaid expenses and other current assets | 46 | -1,246 | 753 | -2,151 |
| Othernon-currentassets | 23 | -14 | 5 | -8 |
| Accounts payable | 1,383 | -343 | -1,262 | 1,721 |
| Accrued expenses and other current liabilities | 1,633 | 571 | 34 | -1,157 |
| Operating lease liabilities | -147 | -593 | -581 | -1,121 |
| Net cash used in operating activities | -18,413 | -14,461 | -17,815 | -27,802 |
| Proceeds from the sale of property and equipment | - | 0 | 15 | 55 |
| Purchase of property and equipment | 19 | 0 | 181 | 27 |
| Net cash used in investing activities | -19 | 0 | -166 | 28 |
| Proceeds from the at-the-market offering, net of offering costs | 1,264 | - | - | - |
| Proceeds from the private placement, net of offering costs | 0 | 0 | 0 | 173,098 |
| Proceeds from the subscription agreement, net of offering costs of 2,000 | - | 0 | 0 | 0 |
| Payment of deferred offering costs | - | -73 | -340 | -55 |
| Cash acquired in connection with the merger, net of transaction costs of 7,412 | - | 0 | 0 | 0 |
| Proceeds from exercise of stock options | 100 | 59 | 6 | 1,166 |
| Payments for employee taxes related to net share settlement of equity awards | 412 | 0 | 0 | 17 |
| Repayment of finance lease obligations | 105 | 127 | 123 | 239 |
| Net cash provided by financing activities | 847 | -141 | -457 | 173,953 |
| Effect of exchange rate changes on cash and cash equivalents | 94 | -35 | -23 | -37 |
| Net (decrease) increase in cash and cash equivalents and restricted cash | -17,491 | -14,637 | -18,461 | 146,142 |
| Cash and cash equivalents and restricted cash as of beginning of period | 254,870 | 269,507 | 141,826 | - |
| Cash and cash equivalents and restricted cash as of end of period | 237,379 | 254,870 | 269,507 | - |
Tectonic Therapeutic, Inc. (TECX)
Tectonic Therapeutic, Inc. (TECX)